In clinical cases, the efficacy of Tra-IR700 mediated PIT is limited to gastric cancers because overexpression of HER2 only account for approximately 20 % of all gastric cancer patients [9, 10], however, this study suggests that the Tra-IR700 mediated PIT and PIT in combination with 5-FU could become effective therapies for HER2-positive cases. Here, ERBB2 is linked to gastric cancer.